Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “pegcetacoplan” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 13
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 13 pipeline programs matching "pegcetacoplan" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

13 results for “pegcetacoplan” Back to intelligence hub

Search results

  1. APL-2, Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial
  2. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial
  3. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials
  4. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial
  5. Pegcetacoplan

    Apellis Europe B.V.

    PNH

    phase 3 small molecule active

    2 trials
  6. Pegcetacoplan

    Apellis Europe B.V.

    C3G

    phase 3 small molecule active

    3 trials
  7. APL-3007, pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 2 small molecule active

    1 trial
  8. Pegcetacoplan

    Apellis Europe B.V.

    Transplant-Associated Thrombotic Microangiopathy

    phase 2 small molecule completed

    1 trial
  9. Pegcetacoplan

    Apellis Europe B.V.

    Neovascular Age-related Macular Degeneration

    phase 2 small molecule terminated

    2 trials
  10. Pegcetacoplan

    Apellis Europe B.V.

    Geographic Atrophy

    phase 2 small molecule completed

    1 trial
  11. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    2 trials
  12. Pegcetacoplan (APL-2)

    Apellis Europe B.V.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial
  13. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.